Information de reference pour ce titreAccession Number: | 01451458-201509010-00012.
|
Author: | Simmons, Bryony 1; Saleem, Jawaad 1; Heath, Katherine 1; Cooke, Graham S. 1; Hill, Andrew 2
|
Institution: | (1)Division of Medicine, Imperial College London (2)Pharmacology and Therapeutics, Liverpool University, United Kingdom
|
Title: | |
Source: | Clinical Infectious Diseases. 61(5):730-740, September 01, 2015.
|
Abstract: | Background. Achievement of a sustained virologic response (SVR) after treatment for Hepatitis C infection is associated with improved outcomes. This meta-analysis aimed to determine the impact of SVR on long-term mortality risk compared with nonresponders in a range of populations.
Methods. An electronic search identified all studies assessing all-cause mortality in SVR and non-SVR patients. Eligible articles were stratified into general, cirrhotic, and populations coinfected with human immunodeficiency virus. The adjusted hazard ratio (95% confidence interval [CI]) for mortality in patients achieving SVR vs non-SVR, and pooled estimates for the 5-year mortality in each group were calculated.
Results. 31 studies (n = 33 360) were identified as suitable for inclusion. Median follow-up time was 5.4 years (interquartile range, 4.9-7.5) across all studies. The adjusted hazard ratio of mortality for patients achieving SVR vs non-SVR was 0.50 (95% CI, .37-.67) in the general population, 0.26 (95% CI, .18-.74) in the cirrhotic group, and 0.21 (.10-.45) in the coinfected group. The pooled 5-year mortality rates were significantly lower for patients achieving SVR compared with non-SVR in all 3 populations.
Conclusions. The results suggest that there is a significant survival benefit of achieving an SVR compared with unsuccessful treatment in a range of populations infected with hepatitis C virus.
(C) Copyright Oxford University Press 2015.
|
Author Keywords: | hepatitis C; sustained virologic response; mortality; survival.
|
References: | 1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117-71.
3. Cooke G, Lemoine M, Thursz M, et al.. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hept 2013; 20:600-1.
4. MSF. The diagnosis and treatment of hepatitis C: a technical landscape. Geneva, Switzerland: MSF Access Campaign, 2014.
5. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland: WHO, 2014.
6. Puoti M, Panzeri C, Rossotti R, Baiguera C. Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. Dig Liver Dis 2014; 46(S5):S206-11.
7. Yau A, Yoshida E. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol 2014; 28:445-51.
8. Innes H, Goldberg D, Dusheiko G, et al.. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. J Heptaol 2014; 60:1118-26.
9. van der Meer A, Wedemeyer H, Feld J, et al.. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol 2014; 60:191-6.
10. Pearlman B, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52:889-900.
11. George S, Bacon B, Brunt E, Mihindukulasuriya K, Hoffman J, Di Bisceglie A. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49:729-38.
12. Berenguer J, Rodriguez E, Miralles P, et al.. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55:728-36.
13. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho S. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci 2014; 59:872-80.
14. Backus L, Boothroyd D, Phillips B, Belperio P, Halloran J, Mole L. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-16.
15. Conjeevaram H, Wahed A, Afdhal N, Howell C, Everhart J, Hoofnagle J. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011; 140:469-77.
16. Arase Y, Suzuki F, Suzuki Y, et al.. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49:739-44.
17. Koretz R, Pleguezuelo M, Arvaniti V, et al.. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013; 1:CD003617.
18. Di Bisceglie A, Shiffman M, Everson G, et al.. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359:2429-41.
19. Coverdale S, Khan M, Byth K, et al.. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol 2004; 99:636-44.
20. Morgan T, Ghany M, Kim H, et al.. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-44.
21. Iacobellis A, Perri F, Valvano M, Caruso N, Niro G, Andriulli A. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol 2011; 9:249-53.
22. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013; 158:280-6.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88.
24. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17:2815-34.
25. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed 5 January 2015.
26. Giannini E, Fasoli A, Botta F, et al.. Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study. J Gastroenterol Hepatol 2001; 16:399-405.
27. Yoshida H, Arakawa Y, Sata M, et al.. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123:483-91.
28. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38:493-502.
29. Veldt B, Saracco G, Boyer N, et al.. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53:1504-8.
30. Kasahara A, Tanaka H, Okanoue T, et al.. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11:148-56.
31. Yu M, Lin S, Chuang W, et al.. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11:985-94.
32. Arase Y, Ikeda K, Suzuki F, et al.. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50:16-23.
33. Innes H, Hutchinson S, Allen S, et al.. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology 2011; 54:1547-58.
34. Reimer J, Hueppe D, Sandow P, et al.. Long-term benefits of sustained virological response (SVR) in patients with chronic hepatitis C (CHC) virus infection: the German Lotos Study. Gastroenterology 2011; 140(5 [suppl 1]):S968.
35. Di Martino V, Crouzet J, Hillon P, Thevenot T, Minello A, Monnet E. Long-term outcome of chronic hepatitis C in a population based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat 2011; 18:493-505.
36. Maruoka D, Imazeki F, Arai M, Kanda T, Fukiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol 2012; 27:291-9.
37. Cozen ML, Ryan JC, Shen H, et al.. Nonresponse to interferon-[alpha] based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One 2013; 8:e61568.
38. Rutter K, Staettermayer A, Ferenci P, et al.. Successful HCV eradication due to antiviral therapy is associated with improved long term outcome of patients with chronic hepatitis C. J Hepatol 2013; 58(suppl 1):S369.
39. Singal A, Dharia T, Malet P, Alqahtani S, Zhang S, Cuthbert J. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open 2013; 3:e003231.
40. Kumar R, Kumar S, Sharma B, Singh J, Sarin S. Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: Pilot study. J Gastroenterol Hepatol 2005; 20:527-35.
41. Braks R, Ganne-Carrie N, Fontaine H, et al.. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13:5648-53.
42. Bruno S, Stroffolini T, Colombo M, et al.. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45:579-87.
43. Mallet V, Gilgenkrantz H, Serpaggi J, et al.. Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399-403.
44. van der Meer AJ, Veldt BJ, Feld JJ, et al.. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-93.
45. Aleman S, Rahbin N, Weiland O, et al.. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57:230-6.
46. Kutala BK, Guedj J, Asselah T, et al.. Impact of treatment against hepatitis C virus on the overall survival in naive patients with advanced liver disease. Antimicrob Agents Chemother 2015; 59:803-10.
47. Limketkai B, Mehta S, Sutcliffe C, et al.. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-8.
48. Peribanez-Gonzalez M, da Silva M, Vilar F, et al.. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection. Ann Hepatol 2013; 12:228-35.
49. Mira J, Rivero-Juarez A, Lopez-Cortes L, et al.. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013; 56:1646-53.
50. Labarga P, Fernandez-Montero J, de Mendoza C, Barreiro P, Soriano V. Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther 2015; 20:65-72.
51. Chen T, Ding E, Seage Lii G, Kim A. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49:1605-15.
52. Thein H, Yi Q, Dore G, Krahn M. Estimation of stag-specific fibrosis progression rates in chornic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-31.
53. El-Kamary S, Jhaveri R, Shardell M. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 2011; 53:150-7.
54. Younossi Z, Kanwal F, Saab S, et al.. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39:518-31.
55. Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ 1998; 316:201.
56. Matthews PC, Jeffery K, Klenerman P, Barnes E, Cooke G. Screening and treatment for hepatitis C: a balanced perspective. BMJ 2015; 350:h644.
57. Foster GR, Gore C, Hudson M, et al.. Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified. BMJ 2015; 350:h998.
|
Language: | English.
|
Document Type: | ARTICLES AND COMMENTARIES.
|
Journal Subset: | Clinical Medicine. Life & Biomedical Sciences.
|
ISSN: | 1058-4838
|
DOI Number: | https://dx.doi.org/10.1093/cid/c...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|